The explosion of cannabidiol, or CBD, merchandise – from fashionable cosmetics to dietary dietary supplements – is catching the eye of the Federal Commerce Fee (“FTC”). The until-very-recently little-known chemical compound presently represents a $5 billion market, in keeping with hashish business analysis consultancy Brightfield Group, up a whopping 700% in worth from final yr, and unsurprisingly, manufacturers, whether or not they be CBD-specific magnificence and skincare manufacturers or established names in luxurious cosmetics, are dashing to the market.
With such an flurry of exercise on this burgeoning new market, and given the relative lack of clear authorized steerage on the subject of the advertising and marketing of CBD-containing merchandise, the FTC lately revealed that it has taken motion in opposition to three presently unnamed firms that “promote oils, tinctures, capsules, gummies, and lotions containing CBD, a chemical compound derived from the hashish plant.”
In line with a September 10 launch from the FTC, every of the businesses that acquired letters had “marketed that its CBD merchandise deal with or remedy critical illnesses and well being situations,” starting from anorexia, bipolar dysfunction, post-traumatic stress dysfunction, anxiousness, and despair to coronary heart illness, most cancers, and “a large spectrum of autoimmune problems.” One firm claims that it has participated in “1000’s of hours of analysis” with Harvard researchers to “bolster its claims that CBD has been ‘clinically confirmed’ to deal with most cancers,” amongst different sicknesses.
Such claims have to be “supported by competent and dependable scientific proof” in accordance with the FTC’s requirement that every one specific and implied promoting claims, together with well being claims, be substantiated earlier than they’re disseminated by the use of an organization’s advertising and marketing.
It’s unclear whether or not the businesses on the receiving finish of the FTC’s letters can really again up their claims, prompting the company to “urge [them] to overview all claims made for his or her merchandise, together with client testimonials, to make sure they’re supported by competent and dependable scientific proof, [as] promoting CBD merchandise with out such substantiation might violate the FTC Act and should lead to authorized motion.”
The businesses have 15 days from the date of the FTC letters to inform the company of “the precise actions they’ve taken to deal with [its] issues.”
Whereas FTC letters are “common,” in keeping with Davis Wright Tremaine LLP’s Helen Goff Foster and Nicole Phillis, they point out rising issues amongst authorities regulators, and state and municipal well being departments, alike, on the subject of “firms making health-related claims pertaining to CBD.” Foster and Phillis word that FTC warning letters usually come previous to the company “initiating a sweep of enforcement actions in opposition to [potentially industry-wide] unfair or misleading practices.”
This marks the second spherical of letters that the FTC, the federal government company that’s tasked with selling client safety, and eliminating and stopping anticompetitive enterprise practices, has despatched to date this yr.
SPONSORED BY VERITAD CANNABIS MARKETING EXCHANGE